within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB27_PabinafuspAlfa;
model PabinafuspAlfa 
   extends Pharmacolibrary.Drugs.ATC.A.A16AB27;

  annotation(Documentation(
    info ="<html><body><p>Pabinafusp alfa is a recombinant fusion protein consisting of human iduronate-2-sulfatase (IDS) coupled with an antibody targeting the human transferrin receptor. It is designed to treat mucopolysaccharidosis type II (MPS II, Hunter syndrome), a lysosomal storage disorder, by facilitating IDS delivery across the blood-brain barrier. Pabinafusp alfa is approved in Japan for the treatment of MPS II.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for typical pediatric patients (children with MPS II) following intravenous infusion. No published peer-reviewed PK studies found as of June 2024.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end PabinafuspAlfa;
